Arovella Therapeutics Ltd has released a press release.
Half Year Report and Appendix 4D
Earlier from Arovella Therapeutics
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella Therapeutics: appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Positive FDA Type D Meeting Outcome